EXCLUSIVE: Avalon GloboCare Tells Benzinga Co's Laboratory Services MSO To Launch Sales Of Proprietary FDA-Registered External Male Catheter Device
Portfolio Pulse from Benzinga Newsdesk
Avalon GloboCare's Laboratory Services MSO is set to launch sales of a proprietary FDA-registered external male catheter device.
August 14, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avalon GloboCare's Laboratory Services MSO is launching sales of a proprietary FDA-registered external male catheter device, which could boost the company's revenue and market presence in the medical device sector.
The launch of a proprietary FDA-registered medical device is a significant development for Avalon GloboCare, likely to positively impact its revenue and market presence. This news is highly relevant and important for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100